A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Description

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.

Conditions

Ulcerative Colitis

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Condition
Ulcerative Colitis
Intervention / Treatment

-

Contacts and Locations

Dothan

Digestive Health Specialists, Dothan, Alabama, United States, 36305

Litchfield Park

Research Solutions of Arizona, Litchfield Park, Arizona, United States, 85340

Phoenix

Valleywise Health Medical Center, Phoenix, Arizona, United States, 85008

Arcadia

InSite Digestive Health Care, Arcadia, California, United States, 91006

Berkeley

Care Access - Berkeley, Berkeley, California, United States, 94705

La Jolla

University of California San Diego, La Jolla, California, United States, 92037

Lancaster

Om Research LLC, Lancaster, California, United States, 93534

Northridge

California Medical Research Associates, Northridge, California, United States, 91324

Rialto

Inland Empire Clinical Trials, LLC, Rialto, California, United States, 92377

San Diego

Clinical Applications Laboratories, Inc., San Diego, California, United States, 92103

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to 80 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Eli Lilly and Company,

    Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

    Study Record Dates

    2027-12